0
0.5
1
1.5
2+
Mortality
0%
Improvement
Relative Risk
Mortality, day 60
-36%
Mortality, day 28
55%
Remdesivir Barrat-Due et al. LATE TREATMENT DB RCT
Is late treatment with remdesivir beneficial for COVID-19?
Double-blind RCT 99 patients in Norway
Trial underpowered to detect differences
c19early.org
Barrat-Due et al., Annals of Internal .., Jul 2021
Favors remdesivir
Favors control